フルテキストURL fulltext.pdf
著者 Ando, Eri| Nakasuka, Takamasa| Kubo, Toshio| Taniguchi, Akihiko| Ninomiya, Kiichiro| Kato, Yuka| Ichihara, Eiki| Ohashi, Kadoaki| Rai, Kammei| Hotta, Katsuyuki| Yamane, Masaomi| Miyahara, Nobuaki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
キーワード pulmonary aspergilloma allergic bronchopulmonary aspergillosis disaster
発行日 2022-02-01
出版物タイトル Internal Medicine
61巻
3号
出版者 JAPAN SOC INTERNAL MEDICINE
開始ページ 379
終了ページ 383
ISSN 0918-2918
NCID AA10827774
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © 2022 The Japanese Society of Internal Medicine
論文のバージョン publisher
PubMed ID 34373373
DOI 10.2169/internalmedicine.7124-21
Web of Science KeyUT 000752787300015
関連URL isVersionOf https://doi.org/10.2169/internalmedicine.7124-21
フルテキストURL fulltext.pdf
著者 Oda, Naohiro| Tabata, Masahiro| Uno, Masatoshi| Umeda, Yuzo| Kato, Hironari| Kubo, Toshio| Senoo, Satoru| Yagi, Takahito| Fujiwara, Toshiyoshi| Maeda, Yoshinobu| Kiura, Katsuyuki|
キーワード pancreas mucinous cystadenocarcinoma carboplatin paclitaxel
発行日 2021-09-15
出版物タイトル Internal Medicine
60巻
18号
出版者 The Japanese Society of Internal Medicine
開始ページ 2967
終了ページ 2971
ISSN 0918-2918
NCID AA10827774
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © 2021 The Japanese Society of Internal Medicine
論文のバージョン publisher
PubMed ID 33814494
DOI 10.2169/internalmedicine.6730-20
Web of Science KeyUT 000697279400013
関連URL isVersionOf https://doi.org/10.2169/internalmedicine.6730-20
フルテキストURL fulltext.pdf
著者 Okawa, Sachi| Rai, Kammei| Fujii, Nobuharu| Gion, Yuka| Ninomiya, Kiichiro| Kato, Yuka| Taniguchi, Akihiko| Kubo, Toshio| Ichihara, Eiki| Ohashi, Kadoaki| Miyahara, Nobuaki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
キーワード EGFR IgG4-related disease marginal zone lymphoma osimertinib
発行日 2021-09-01
出版物タイトル Internal Medicine
60巻
17号
出版者 The Japanese Society of Internal Medicine
開始ページ 2831
終了ページ 2837
ISSN 0918-2918
NCID AA10827774
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © 2021 The Japanese Society of Internal Medicine
論文のバージョン publisher
PubMed ID 33775999
DOI 10.2169/internalmedicine.6470-20
Web of Science KeyUT 000695856000020
関連URL isVersionOf https://doi.org/10.2169/internalmedicine.6470-20
フルテキストURL fulltext20210810-3.pdf
著者 Nishii, Kazuya| Ohashi, Kadoaki| Watanabe, Hiromi| Makimoto, Go| Nakasuka, Takamasa| Higo, Hisao| Ninomiya, Kiichiro| Kato, Yuka| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
キーワード epidermal growth factor receptor osimertinib bevacizumab cetuximab hypoxia‑inducible factor‑1α transforming growth factor‑α
発行日 2021-7-7
出版物タイトル Oncology Letters
22巻
3号
出版者 Spandidos Publications
開始ページ 639
ISSN 1792-1074
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © Nishii et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
論文のバージョン publisher
DOI 10.3892/ol.2021.12900
Web of Science KeyUT 000678494600001
関連URL isVersionOf https://doi.org/10.3892/ol.2021.12900
フルテキストURL fulltext.pdf
著者 Watanabe, Hiromi| Ichihara, Eiki| Kayatani, Hiroe| Makimoto, Go| Ninomiya, Kiichiro| Nishii, Kazuya| Higo, Hisao| Ando, Chihiro| Okawa, Sachi| Nakasuka, Takamasa| Kano, Hirohisa| Hara, Naofumi| Hirabae, Atsuko| Kato, Yuka| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ohashi, Kadoaki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
発行日 2021-01-07
出版物タイトル Cancer science
出版者 Wiley
ISSN 1347-9032
NCID AA11808050
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © 2021 The Authors.
論文のバージョン publisher
PubMed ID 33410241
NAID 120007008532
DOI 10.1111/cas.14801
Web of Science KeyUT 000630136900001
関連URL isVersionOf https://doi.org/10.1111/cas.14801
フルテキストURL fulltext.pdf
著者 Katayama, Hideki| Tabata, Masahiro| Kubo, Toshio| Kiura, Katsuyuki| Matsuoka, Junji| Maeda, Yoshinobu|
キーワード Weekend chemotherapy Outpatient Social burden Cancer patient
発行日 2020-07-04
出版物タイトル Supportive Care in Cancer
29巻
出版者 Springer
開始ページ 1287
終了ページ 1297
ISSN 0941-4355
NCID AA10996793
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
論文のバージョン publisher
PubMed ID 32621265
DOI 10.1007/s00520-020-05575-x
Web of Science KeyUT 000545922600001
関連URL isVersionOf https://doi.org/10.1007/s00520-020-05575-x
フルテキストURL fulltext.pdf
著者 Nishii, Kazuya| Ohashi, Kadoaki| Tamura, Tomoki| Ninomiya, Kiichiro| Matsubara, Takehiro| Senoo, Satoru| Kano, Hirohisa| Watanabe, Hiromi| Oda, Naohiro| Makimoto, Go| Higo, Hisao| Kato, Yuka| Ninomiya, Takashi| Kubo, Toshio| Yamamoto, Hiromasa | Tomida, Shuta| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Maeda, Yoshinobu| Kiura, Katsuyuki|
キーワード non-small cell lung cancer epidermal growth factor receptor mutations droplet digital PCR exhaled breath condensate EGFR-TKIs
発行日 2020-12
出版物タイトル Oncology Letters
20巻
6号
出版者 Spandidos Publications
開始ページ 393
ISSN 1792-1074
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
論文のバージョン publisher
PubMed ID 33193853
DOI 10.3892/ol.2020.12256
Web of Science KeyUT 000595649300005
関連URL isVersionOf https://doi.org/10.3892/ol.2020.12256
著者 後藤田 達洋| 川野 誠司| 河野 吉泰| 三浦 公| 神崎 洋光| 岩室 雅也| 河原 祥朗| 田中 健大| 吉野 正| 白川 靖博| 田端 雅弘| 谷本 光音| 岡田 裕之|
発行日 2016-12-01
出版物タイトル 岡山医学会雑誌
128巻
3号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/54607
フルテキストURL 70_5_425.pdf
著者 Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi|
抄録 Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer.
キーワード breast cancer phase I trial docetaxel
Amo Type Clinical Study Protocols
出版物タイトル Acta Medica Okayama
発行日 2016-10
70巻
5号
出版者 Okayama University Medical School
開始ページ 425
終了ページ 427
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27777441
Web of Science KeyUT 000388098700018
タイトル(別表記) A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy
フルテキストURL 127_127.pdf
著者 木浦 勝行| 堀田 勝幸| 佐藤 晃子| 大橋 圭明| 二宮 崇| 南 大輔| 田端 雅弘| 久保 寿夫| 加藤 有加| 平田 泰三|
キーワード 臨床研究中核病院 国立研究開発法人日本医療研究開発機構 文部科学省橋渡し研究加速ネットワークプログラム HER2-CS study trastuzumab emtansine
出版物タイトル 岡山医学会雑誌
発行日 2015-08-03
127巻
2号
開始ページ 127
終了ページ 132
ISSN 0030-1558
関連URL isVersionOf https://doi.org/10.4044/joma.127.127
言語 Japanese
著作権者 Copyright (c) 2015 岡山医学会
論文のバージョン publisher
DOI 10.4044/joma.127.127
NAID 130005096256
著者 Ochi, Nobuaki| Takigawa, Nagio| Harada, Daijiro| Yasugi, Masayuki| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2014-03-10
出版物タイトル Experimental Cell Research
322巻
1号
資料タイプ 学術雑誌論文
著者 Nogami, Naoyuki| Hotta, Katsuyuki| Kuyama, Shoichi| Kiura, Katsuyuki| Takigawa, Nagio| Chikamori, Kenichi| Shibayama, Takuo| Kishino, Daizo| Hosokawa, Shinobu| Tamaoki, Akihiko| Harita, Shingo| Tabata, Masahiro| Ueoka, Hiroshi| Shinkai, Tetsu| Tanimoto, Mitsune|
発行日 2011-10
出版物タイトル Lung Cancer
74巻
1号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/32866
フルテキストURL fulltext.pdf
著者 Fujimoto, Nobukazu| Kiura, Katsuyuki| Takigawa, Nagio| Fujiwara, Yoshiro| Toyooka, Shinichi| Umemura, Shigeki| Tabata, Masahiro| Ueoka, Hiroshi| Tanimoto, Mitsune|
抄録 <p>We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were &#60;70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2;the cycle was repeated every 3 weeks. The objective response rate was 39.1% (95% confidence interval:18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy;of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%);no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.</p>
キーワード cisplatin docetaxel irinotecan triplet chemotherapy gefitinib
Amo Type Original Article
出版物タイトル Acta Medica Okayama
発行日 2010-02
64巻
1号
出版者 Okayama University Medical School
開始ページ 33
終了ページ 37
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 20200582
Web of Science KeyUT 000274868300005
JaLCDOI 10.18926/AMO/31714
フルテキストURL fulltext.pdf
著者 Kawada, Kazuhiko| Yonei, Toshiro| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Takigawa, Nagio| Harada, Mine| Tanimoto, Mitsune|
抄録 <p>When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, especially the platinum analogues and anthracyclines/anthracenedione.</p>
キーワード chemosensitivity test 3-(4 5-dimethylthiazol-2-yl)-2 5-diphenyltertrazolium bromide (MTT) assay clonogenic assay
Amo Type Article
出版物タイトル Acta Medica Okayama
発行日 2002-06
56巻
3号
出版者 Okayama University Medical School
開始ページ 129
終了ページ 134
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 12108583
Web of Science KeyUT 000176521200002
JaLCDOI 10.18926/AMO/31705
フルテキストURL fulltext.pdf
著者 Takata, Ichiro| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Takigawa, Nagio| Katayama, Hideki| Takemoto, Mitsuhiro| Hiraki, Yoshio| Harada, Mine| Tanimoto, Mitsune|
抄録 <p>A pilot study was conducted to assess the efficacy and feasibility of daily low-dose cisplatin with concurrent thoracic irradiation for clinically unresectable non-small-cell lung cancer (NSCLC). Patients with inoperable NSCLC who had poor risk factors such as advanced age, poor performance status, poor lung function, or concomitant active malignancy were entered into the study. Low-dose cisplatin (6 mg/m2) was administered daily before concurrent thoracic irradiation (2 Gy/day; total dose of 60 Gy) was given. Twenty-five patients were registered. The majority of the patients had either stage IIIA (24.0%) or stage IIIB (60.0%) disease. Fifteen patients (60.0%) completed the planned treatment. Both chemotherapy and radiotherapy were stopped in 3 patients (12.0%) due to poor response, and 7 patients (28.0%) partly received radiotherapy alone as a result of their toxicity response. The proportion of total administered dose to planned dose was 90.9% for chemotherapy and 99.3% for radiotherapy, which were comparable to those in previous studies for LA-NSCLC patients without poor risk factors. Grade 3 leukopenia and neutropenia developed in 14 patients (56.0%) and 10 patients (40.0%), respectively, but grade 4 toxicity was not encountered. Grade 3 pneumonitis and esophagitis were observed in 4 patients (16.0%) and 2 patients (8.0%), respectively. The overall response rate was 60.0%. The median survival time was 22 months, and the 2-year survival rate was 50.3%. Daily low-dose cisplatin and concurrent thoracic irradiation were well tolerated even by poor-risk patients with NSCLC, and showed a therapeutic efficacy similar to that for good-risk patients.</p>
キーワード non-small-cell lung cancer concurrent chemoradiotherapy low-dose cisplatin poor-risk factor
Amo Type Article
出版物タイトル Acta Medica Okayama
発行日 2002-10
56巻
5号
出版者 Okayama University Medical School
開始ページ 261
終了ページ 266
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 12530510
Web of Science KeyUT 000178668100007
JaLCDOI 10.18926/AMO/31626
フルテキストURL fulltext.pdf
著者 Matsushita, Akio| Tabata, Masahiro| Ueoka, Hiroshi| Kiura, Katsuyuki| Shibayama, Takuo| Aoe, Keisuke| Kohara, Hiroyuki| Harada, Mine|
抄録 <p>We established a drug sensitivity panel consisting of 24 human lung cancer cell lines. Using this panel, we evaluated 26 anti-cancer agents: three alkylators, three platinum compounds, four antimetabolites, one topoisomerase I inhibitor, five topoisomerase II inhibitors, seven antimitotic agents and three tyrosine kinase inhibitors. This panel showed the following: a) Drug sensitivity patterns reflected their clinically-established patterns of action. For example, doxorubicin and etoposide were shown to be active against small cell lung cancer cell lines and mitomycin-C and 5-fluorouracil were active against non-small cell lung cancer cell lines, in agreement with clinical data. b) Correlation analysis of the mean graphs derived from the logarithm of IC50 values of the drugs gave insight into the mechanism of each drug's action. Thus, two drug combinations with reverse or no correlation, such as the combination of cisplatin and vinorelbine, might be good candidates for the ideal two drug combination in the treatment of lung cancer, as is being confirmed in clinical trials. c) Using cluster analysis of the cell lines in the panel with their drug sensitivity patterns, we could classify the cell lines into four groups depending on the drug sensitivity similarity. This classification will be useful to elucidate the cellular mechanism of action and drug resistance. Thus, our drug sensitivity panel will be helpful to explore new drugs or to develop a new combination of anti-cancer agents for the treatment of lung cancer.</p>
キーワード drug screening system MTT assay lung cancer cell line drug resistance
Amo Type Article
出版物タイトル Acta Medica Okayama
発行日 1999-04
53巻
2号
出版者 Okayama University Medical School
開始ページ 67
終了ページ 75
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
Web of Science KeyUT 000080058700002
JaLCDOI 10.18926/AMO/31598
フルテキストURL fulltext.pdf
著者 Kiura, Katsuyuki| Ohnoshi, Taisuke| Tabata, Masahiro| Shibayama, Takuo| Kimura, Ikuro|
抄録 A subline highly resistant to Adriamycin (SBC-3/ADM100) was isolated in vitro from the human small cell lung cancer cell line, SBC-3, by culturing in progressively higher concentrations of Adriamycin. The SBC-3/ADM100 cells were 106-fold more resistant to the drug than the parent cells in an inhibitory concentration of 50% determined by the MTT assay. The population-doubling time was much longer in SBC-3/ADM100 than in the parent cells. Northern blot hybridization revealed marked overexpression of the MDR1 mRNA in the resistant cells. P-glycoprotein overexpression and a decrease in intracellular accumulation of Adriamycin were demonstrated in SBC-3/ADM100, indicating that outward drug transport was the major mechanism of resistance in this subline. Additionally, a significant elevation of the intracellular glutathione content coupled with the glutathione S-transferase (GST) pi level and a decrease in DNA topoisomerase II (Topo II) activity were noted in this resistant subline. These results indicate that the mechanism of resistance to Adriamycin is multifactorial; involving altered growth characteristics, an enhanced outward transport, enhanced drug detoxification process, and decreased target enzyme activity. The resistant subline will serve as a useful tool in the search for ways to overcome drug resistance.
キーワード Adriamycin-resistant cell line MDR1 mRNA glutathione glutathione S-transferasse π DNA topoisomerase II
Amo Type Article
出版物タイトル Acta Medica Okayama
発行日 1993-06
47巻
3号
出版者 Okayama University Medical School
開始ページ 191
終了ページ 197
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 Copyright © 1999 Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 8104372
Web of Science KeyUT A1993LL12400008
関連URL http://ousar.lib.okayama-u.ac.jp/metadata/6296
JaLCDOI 10.18926/AMO/31590
フルテキストURL fulltext.pdf
著者 Segawa, Yoshihiko| Ohnoshi, Taisuke| Hiraki, Shunkichi| Ueoka, Hiroshi| Kiura, Katsuyuki| Kamei, Haruhito| Tabata, Masahiro| Shibayama, Takuo| Miyatake, Kazuyo| Genda, ken-ichi| Matsumura, Tadashi| Kimura, Ikuro|
抄録 <p>In an attempt to elucidate the tumor properties relating to responsiveness to chemotherapy, we examined immunohistochemically the expression of P-glycoprotein (P-gp) and carcinoembryonic antigen (CEA) in small cell lung cancer (SCLC) tumors. Tumor specimens from 33 patients were obtained at the time of diagnosis and relapse. Four patients expressed P-gp in their initial tumors, and 7 others did in recurrent tumors. The overall response rate to chemotherapy of the initial tumors was 75% for P-gp-positive initial tumors and 86% for P-gp-negative tumors, whereas the disease-free and overall survival times were significantly shorter in the former than the latter. Three patients showed CEA in their initial tumors, and 5 others did in recurrent tumors. The patients with CEA-positive initial tumors tended to relapse earlier than those with CEA-negative tumors. In addition, recurrent tumors expressing CEA were resistant to salvage chemotherapy. A clear correlation between CEA expression by tumors and the CEA level in the serum was observed at diagnosis as well as at relapse. These findings indicate that P-gp and/or CEA expression by a tumor and elevated CEA level in the serum may predict refractoriness of the tumor to chemotherapy.</p>
キーワード small cell lung cancer immunohistochemistry drug resistance P-glycoprotein carcinoembryonic antigen
Amo Type Article
出版物タイトル Acta Medica Okayama
発行日 1993-06
47巻
3号
出版者 Okayama University Medical School
開始ページ 181
終了ページ 189
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 8104371
Web of Science KeyUT A1993LL12400007
JaLCDOI 10.18926/AMO/31553
フルテキストURL fulltext.pdf
著者 Tabata, Masahiro| Ohnoshi, Taisuke| Ueoka, Hiroshi| Kiura, Katsuyuki| Kimura, Ikuro|
抄録 <p>We report a preliminary study to determine whether MDR1 gene expression level in small cell lung cancer (SCLC) tumors is a useful predictor of tumor response to chemotherapy and patient survival in association with myc amplification in the tumor. We analyzed 18 patients with SCLC receiving adriamycin and etoposide combination chemotherapy between August 1989 and November 1991; 16 males and 2 females, median age of 68 years, and 7 with limited disease and 11 with extensive disease. MDR1 mRNA expression level and myc family gene amplification were simultaneously determined by polymerase chain reaction using transbronchial biopsy specimens which were obtained at diagnosis. Patients with tumors expressing low MDR1 mRNA responded more favorably to chemotherapy than those with tumors expressing high MDRI mRNA, however, the difference in tumor response was statistically not significant (84.6% versus 40%). The overall survival was significantly shorter in the latter than in the former (7.2 months versus 11.7 months; p = 0.023). The survival of the 4 patients with tumor showing myc family gene amplification was almost identical to that of patients with tumors showing no amplification of the gene (8.2 months versus 8.8 months; p = 0.73). Multivariate Cox's regression analysis supports the notion that MDR1 may be a useful independent prognostic factor.</p>
キーワード small cell lung cancer MDR1 mRNA expression myc gene amplification prognostic factor
Amo Type Article
出版物タイトル Acta Medica Okayama
発行日 1993-08
47巻
4号
出版者 Okayama University Medical School
開始ページ 243
終了ページ 248
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 8213218
Web of Science KeyUT A1993LV73800004
JaLCDOI 10.18926/AMO/31552
フルテキストURL fulltext.pdf
著者 Yonei, Toshiro| Ohnoshi, Taisuke| Hiraki, Shunkichi| Ueoka, Hiroshi| Kiura, Katsuyuki| Moritaka, Tomonori| Shibayama, Takuo| Tabata, Masahiro| Segawa, Yoshihiko| Takigawa, Nagio| Kimura, Ikuro|
抄録 <p>Antitumor activities of five platinum analogs, including cisplatin, carboplatin, 254-S, DWA2114R, and NK121, were compared using five human lung cancer cell lines and 19 tumor specimens obtained from lung cancer patients. The antitumor activity was evaluated by determining the ratio of the maximum tolerated dose of each drug to the 70% tumor growth inhibitory concentration in a colony assay. Cisplatin was the most potent agent, followed by 254-S and carboplatin. DWA2114R and NK121 were less potent than cisplatin and 254-S. Cross-resistance to adriamycin was also investigated using an adriamycin-resistant small cell lung cancer subline, SBC -3/ADM30. SBC-3/ADM30 was 1.7- to 4.0-fold more resistant to cisplatin, carboplatin, NK121, and DWA2114R, than was the parent line, SBC-3, and the subline was 2.0-fold more sensitive to 254-S. Using SBC-3, in vitro combination effects of etoposide and cisplatin, carboplatin, or 254-S were evaluated by the median-effect principle. Synergism was noted when cisplatin and etoposide were combined at a fixed molar ratio of 1:1. Combination of carboplatin and etoposide showed an additive effect. The combination of 254-S and etoposide was antagonistic at low concentrations, but was markedly synergistic at higher concentrations. These data suggested the efficacy of 254-S in the treatment of lung cancer.</p>
キーワード platinum analogs antitumor activity lung cancer colony assay combination effect
Amo Type Article
出版物タイトル Acta Medica Okayama
発行日 1993-08
47巻
4号
出版者 Okayama University Medical School
開始ページ 233
終了ページ 241
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 8213217
Web of Science KeyUT A1993LV73800003